Sintilimab bevacizumab gastric cancer trial Zhongshan Hospital
Summary
National Library of Medicine registered a new clinical trial (NCT07515625) on ClinicalTrials.gov evaluating sintilimab combined with bevacizumab for treating advanced gastric or gastroesophageal junction adenocarcinoma at Zhongshan Hospital in China. The single-arm Phase 2 study will enroll approximately 20 participants.
What changed
A new clinical trial registration (NCT07515625) was added to ClinicalTrials.gov. The trial evaluates sintilimab combined with bevacizumab in patients with advanced gastric or gastroesophageal junction adenocarcinoma at Zhongshan Hospital in China. Sintilimab is an anti-PD-1 monoclonal antibody and bevacizumab is an anti-VEGF monoclonal antibody. This Phase 2 single-arm study plans to enroll approximately 20 participants.
This is a clinical trial registration notice on a public government registry. Healthcare providers, clinical investigators, and pharmaceutical companies involved in oncology research may monitor this registry for study updates and results.
What to do next
- Monitor for updates
Source document (simplified)
Show glossary
Related changes
Get daily alerts for ClinicalTrials.gov
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.